GVR Report cover U.S. Cannabinoids Market Size, Share & Trends Report

U.S. Cannabinoids Market Size, Share & Trends Analysis Report By Product (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabigerol (CBG), Cannabichromene (CBC); Cannabinol (CBN)), And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-255-9
  • Number of Pages: 80
  • Format: Electronic (PDF)
  • Historical Range: 2016 - 2020
  • Industry: Healthcare

Report Overview

The U.S. cannabinoids market size was valued at USD 14.6 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 16.2% from 2021 to 2030. Factors, such as the rising number of consumers opting for cannabinoid-based products and increasing awareness concerning cannabis and cannabinoid products drive the market growth. The utilization of cannabinoids for different medical conditions has gained momentum in the country in recent years. Affirmative government regulations about cannabinoids have proven to be beneficial in increasing the number of players entering the market. Furthermore, the rising demand for minor and major cannabinoids and positive research carried out for claiming their benefits in various health conditions have helped boost awareness about cannabinoid use. However, the high production and extraction costs, mainly concerning minor cannabinoids, are expected to hinder the market growth.

U.S. cannabinoids market size, by product type, 2020 - 2030 (USD Billion)

Furthermore, shifting in the adoption trend towards cannabinoid-based products from traditional medicines due to positive health benefits provided by them in certain health conditions is a pioneering factor boosting the market growth. Growing research investigating the impact of cannabinoids on conditions such as epilepsy, cancer, chronic pain, arthritis, metabolic issues, and neurological disorders is further bolstering the growth. For instance, as per a survey quoted in an article published in Life Beyond Numbers in 2020, around 42% of the consumers using CBD stopped using traditional medications and preferred CBD products.

In addition, the growing demand for cannabinoid products in the country, coupled with increasing sales of cannabinoid products is yet another factor supporting the growth. The growth can be signified through an increase in retail sales, online sales as well as internet searches for cannabis and related products. For instance, as per a 2019 research provided by Jama Network, the web searches for CBD increased from 125.9% from 2016 to 2017 to 160.4% from 2017 to 2018.

With the advent of sanctioning of the Farm bill in 2018, various opportunities were created in the market owing to the legalization of CBD and THC (in some states). This legalization has led to the opening of the country’s market for major companies to enter and establish their foothold. It is further positively impacting the market growth. In addition, post-legalization, an upsurge in dispensary, manufacturing, and cultivation licenses has further promoted market growth. For instance, according to Canix, as of 2021, there are around 8550 retail cannabis licenses sanctioned in the U.S. It is a substantially high number and is anticipated to increase at a faster growth rate in the coming years.

Moreover, the high price of cannabinoid products and the expensive extraction process are some of the factors impeding the market growth. Minor cannabinoids, found in very few quantities in the cannabis plant, are difficult to extract and require a higher amount of biomass. For instance, CBD accounts for around 20% of the total cannabis plant, as compared to CBG which accounts for approximately 1%. Hence, around 20x biomass is required for extracting the same quantities of CBG as compared to CBD. It thus hampers the market growth. However, due to the rising popularity of minor cannabinoids, coupled with the increasing adoption of major cannabinoids such as CBD and THC, players are anticipated to increase production, thereby reducing the hurdle in the forthcoming years.

In addition, the COVID-19 pandemic has significantly impacted the cannabis industry. Nationwide lockdowns and disruptions in the supply chain during the pandemic have led to a reduction in revenue generation. In addition, the reduction in production and manufacturing of cannabinoid-based products along with panic buying scenarios in the country in the initial months of the pandemic are some of the other factors that impacted the U.S. cannabinoids market during the pandemic.

Product Insights

Cannabidiol (CBD) dominated the market with a revenue share of 27.2% in 2021. This high share is attributable to the rising adoption of CBD for various applications such as metabolic disorders, epilepsy, neurological disorders, arthritis, Alzheimer’s disease, diabetes, and pain management. In addition, rising strategic initiatives in the form of product launch, clinical trials, and rising cultivation of CBD-rich cultivars by cultivators in the country are further increasing the penetration and adoption of CBD products. Such initiatives signify growing demand, thereby boosting the market growth.

U.S. cannabinoids market share, by product, 2021 (%)

Tetrahydrocannabivarin (THCV) is anticipated to expand at the fastest CAGR of 18.4% during the forecast period. This growth is attributable to rising awareness with regards to the benefits of THCV for a few medical conditions, such as metabolic disorders, pain management, and diabetes. In addition, an increase in the number of players aiming at the production of THCV is further projected to fuel the market growth.

Key Companies & Market Share Insights

Competition is significant amongst the existing players owing to the increasing acceptance of cannabinoid-based products and rising demand. Some of the key players operating in the market are Mile High Labs International; Global Cannabinoids; GenCanna; LaurelCrest; CBD INC.; Rhizo Sciences; Precision Plant Molecules; Fresh Bros Hemp Company; BulKanna; Zero Point Extraction; and High Purity Natural Products.

Furthermore, strategic alliances with other market players in the form of product launches, mergers and acquisitions, production scale-up, collaborations, and partnerships, as well as increasing R&D in the field of cannabinoids are some of the initiatives being undertaken by key market players. In 2021, GenCanna announced the acquisition of CBD Capital Ltd. It will help in strengthening the foothold of GenCanna in the cannabis industry at the local as well as global levels. Some prominent players in the U.S. cannabinoids market include:

  • Mile High Labs International

  • Global Cannabinoids

  • GenCanna


  • Precision Plant Molecules

  • Rhizo Sciences

  • LaurelCrest

  • Fresh Bros Hemp Company

  • BulKanna

  • High Purity Natural Products

  • Zero Point Extraction

U.S. Cannabinoids Market Report Scope

Report Attribute


Market size value in 2022

USD 18.1 billion

Revenue forecast in 2030

USD 60.4 billion

Growth rate

CAGR of 16.2% from 2022 to 2030

Base year for estimation


Historical data

2016 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered


Country scope


Key companies profiled

Mile High Labs International; Global Cannabinoids; GenCanna; CBD INC.; Precision Plant Molecules; Rhizo Sciences; LaurelCrest; Fresh Bros Hemp Company; BulKanna; High Purity Natural Products; Zero Point Extraction

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


U.S. Cannabinoids Market Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2030. For this study, Grand View Research, Inc. has segmented the U.S. cannabinoids market report based on product:

  • Product Outlook (Revenue, USD Million, 2016 - 2030)

    • Tetrahydrocannabinol (THC)

    • Cannabidiol (CBD)

    • Cannabigerol (CBG)

    • Cannabichromene (CBC)

    • Cannabinol (CBN)

    • Tetrahydrocannabivarin (THCV)

    • Cannabigerolic acid (CBGA)

    • Others (Cannabidiolic Acid (CBDA), Cannabidivarin (CBDV), and Other Minor Cannabinoids)

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon